First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
about
CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity.The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation.Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.CD28 between tolerance and autoimmunity: the side effects of animal models.CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates
P2860
First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
First-in-Human Study in Health ...... y Fragment Antagonist of CD28.
@en
First-in-Human Study in Health ...... y Fragment Antagonist of CD28.
@nl
type
label
First-in-Human Study in Health ...... y Fragment Antagonist of CD28.
@en
First-in-Human Study in Health ...... y Fragment Antagonist of CD28.
@nl
prefLabel
First-in-Human Study in Health ...... y Fragment Antagonist of CD28.
@en
First-in-Human Study in Health ...... y Fragment Antagonist of CD28.
@nl
P2093
P2860
P50
P356
P1476
First-in-Human Study in Health ...... dy Fragment Antagonist of CD28
@en
P2093
Caroline Mary
Cecile Braudeau
Gilles Blancho
Ian Anderson
Jean-Paul Soulillou
Jos Lempoels
Maryvonne Hiance
Nicolas Poirier
Steven Ramael
Virginie Thepenier
P2860
P304
P356
10.4049/JIMMUNOL.1601538
P407
P577
2016-11-14T00:00:00Z